AgeX Therapeutics (AgeX Therapeutics) ROCE % : -185.22% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AgeX Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -185.22%.

AgeX Therapeutics ROCE % Historical Data

The historical data trend for AgeX Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics ROCE % Chart

AgeX Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-202.96

-736.82

AgeX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-185.22

AgeX Therapeutics ROCE % Calculation

AgeX Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.911	/	( ( (3.241 - 10.078)	+	(11.965 - 5.914) )	/ 2 )
	=	-9.911	/	( (-6.837	+	6.051)	/ 2 )
	=	-9.911	/	-0.393
	=	2,521.88 %

AgeX Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-13.944	/	( ( (12.21 - 3.204)	+	(11.965 - 5.914) )	/ 2 )
	=	-13.944	/	( ( 9.006	+	6.051 )	/ 2 )
	=	-13.944	/	7.5285
	=	-185.22 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

AgeX Therapeutics (AMEX:AGE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AgeX Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AgeX Therapeutics (AgeX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0X4:Germany 0X4:Germany

Address

1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501

Website

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

Executives

Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae	officer: Chief Financial Officer	C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May	director	965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West	director, officer: Chief Executive Officer	AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall	officer: Corporate Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg	officer: Vice President-Research	935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin	director	3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd	10 percent owner	1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik	officer: Chief Operating Officer	C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501